Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

IMPORTANCE: Hormone receptor–positive, ERBB2 (formerly HER2/neu)-negative metastatic breast cancer (HR-positive, ERBB2-negative MBC) is treated with targeted therapy, endocrine therapy, chemotherapy, or combinations of these modalities; however, evaluating the increasing number of treatment options...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xuanyi, Beeghly-Fadiel, Alicia, Bhavnani, Suresh K., Tavana, Hossein, Rubinstein, Samuel M., Gyawali, Bishal, Riaz, Irbaz Bin, Fernandes, H. Deepika, Warner, Jeremy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008500/
https://www.ncbi.nlm.nih.gov/pubmed/35416993
http://dx.doi.org/10.1001/jamanetworkopen.2022.4361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008500/
https://www.ncbi.nlm.nih.gov/pubmed/35416993
http://dx.doi.org/10.1001/jamanetworkopen.2022.4361

Ejemplares similares